Table 2.
Cox proportional hazards survival regression analysis of the predictive value of clinical-pathological variables and impaired activated protein C (APC) functionality on progression-free (PFS) and overall survival (OS) of breast cancer patients
| PFS | OS | |||||
|---|---|---|---|---|---|---|
|
|
|
|||||
| Variable | Code | N. | HR (95% C.I.) | p-Value | HR (95% C.I.) | p-Value |
| Molecular type | Basal like TN | 39 | ||||
| LLA | 104 | |||||
| LLB | 136 | |||||
| HER2 pos | 11 | 0.51 (0.31-0.81) | 0.0051 | 0.55 (0.15-1.93) | 0.347 | |
| Stage of disease | I | 69 | ||||
| II | 105 | |||||
| III | 72 | |||||
| IV | 4 | |||||
| Metastatic | 40 | 1.76 (1.10-2.81) | 0.018 | 4.22 (1.58-11.2) | 0.004 | |
| Estrogen receptors | Negative | 56 | ||||
| Positive | 234 | 0.71 (0.31-1.64) | 0.422 | 1.84 (0.24-14.4) | 0.561 | |
| Progesterone receptors | Negative | 79 | ||||
| Positive | 211 | 1.78 (0.79-4.00) | 0.162 | 0.85 (0.21-3.45) | 0.822 | |
| HER2/NEU status | Negative | 239 | ||||
| Positive | 51 | 0.70 (0.32-1.51) | 0.361 | 0.56 (0.11-2.95) | 0.496 | |
| Ki67 proliferation index | Low | 93 | ||||
| High | 197 | 2.08 (1.04-4.16) | 0.040 | 1.53 (0.32-7.45) | 0.597 | |
| Type of treatment | ||||||
| Neoadjuvant | 50 | 6.32 (2.08-19.2) | 0.001 | 0.68 (0.05-8.84) | 0.767 | |
| Hormone CT | 45 | 1.84 (0.69-4.90) | 0.223 | 0.38 (0.04-3.91) | 0.413 | |
| Adjuvant CT | 152 | 2.05 (0.72-5.85) | 0.181 | 0.00 (0.00-3.97) | 0.960 | |
| Metastatic | 44 | 9.57 (1.83-49.9) | 0.007 | 0.37 (0.02-7.68) | 0.521 | |
| Impaired APC function | No | 232 | ||||
| Yes | 58 | 2.71 (1.51-4.88) | 0.001 | 1.53 (0.45-5.25) | 0.499 | |
C.I.: Confidence interval; HR: Hazard ratio; ER: estrogen receptors; PR: progesterone receptors; HER2: Human Epidermal Growth Factor Receptor 2. Numbers in parentheses represent percentages. CT: chemotherapy.